<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01224210</url>
  </required_header>
  <id_info>
    <org_study_id>Ambrisentan Portopulm Study</org_study_id>
    <nct_id>NCT01224210</nct_id>
  </id_info>
  <brief_title>Ambrisentan in Patients With Porto-pulmonary Hypertension A Multicenter Open Label Trial</brief_title>
  <acronym>Portopulm</acronym>
  <official_title>Ambrisentan in Patients With Porto-pulmonary Hypertension A Multicenter Open Label Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tufts Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Tufts Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an Open Label, Multicenter, pilot clinical trial to assess the efficacy and safety of&#xD;
      an oral selective Endothelin Receptor Antagonist (ambrisentan) in patients with&#xD;
      portopulmonary hypertension.&#xD;
&#xD;
      Preliminary evidence suggests that ambrisentan is safe and effective in patients with&#xD;
      portopulmonary hypertension. The goal of therapy for these patients is to improve symptoms of&#xD;
      dyspnea and to improve pulmonary hemodynamics to a mean pulmonary artery pressure &lt;35 mm Hg&#xD;
      in order to make patients eligible for liver transplantation. Therefore, the primary&#xD;
      endpoints for this study will include 6 minute walk distance (6MWD) and pulmonary vascular&#xD;
      resistance (PVR).&#xD;
&#xD;
      Eligible subjects will receive 5 mg ambrisentan once-daily for the first 4 weeks. After the&#xD;
      initial 4-week period, investigators will increase study drug dose to 10 mg once daily (both&#xD;
      5 mg and 10 mg doses are FDA approved). If 10 mg is not tolerated in the opinion of&#xD;
      investigator, then the investigator may decrease the dose back to 5 mg once daily. Primary&#xD;
      outcome is a change in both the 6 Minute Walk Distance and in Pulmonary Vascular Resistance&#xD;
      from baseline to Week 24. Subjects will be monitored with liver function tests (LFT) every 2&#xD;
      weeks for the first 8 weeks, then every 4 weeks thereafter. These safety laboratory tests may&#xD;
      be performed at a local phlebotomy laboratory or at the Investigator clinic. In addition, the&#xD;
      Investigator will assess each subject for safety and efficacy at Week 4, Week 12, and Week&#xD;
      24. Following Week 24, subjects will be assessed for safety and efficacy every 12 weeks.&#xD;
      Patients will be followed for a total of 1 year. After 1 year, if the Investigator feels that&#xD;
      continuing the treatment will be beneficial to the patients, they will be provided with&#xD;
      ambrisentan by Gilead Pharmaceuticals, free of charge.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 2010</start_date>
  <completion_date type="Actual">March 2020</completion_date>
  <primary_completion_date type="Actual">October 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Pulmonary Vascular Resistance</measure>
    <time_frame>from baseline to Week 24</time_frame>
    <description>Change in Pulmonary Vascular Resistance from baseline to Week 24 for all patients (using cardiac output [CO] measured by the thermodilution method and reported as percent difference from baseline).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>6 Minute Walk Distance</measure>
    <time_frame>Change from baseline to Week 24</time_frame>
    <description>Change from baseline in 6 Minute Walk Distance to Week 24 for all patients. (difference measured in meters).</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Portopulmonary Hypertension</condition>
  <arm_group>
    <arm_group_label>Ambrisentan (24 Weeks), Extension (4 Weeks)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Open Label Ambrisentan</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ambrisentan</intervention_name>
    <description>Ambrisentan once-daily in the morning with or without food. The adult dose selected for this study will be 5 mg for the first 4 weeks. After the initial 4 weeks the dose will be increased to 10mg (available doses are 5, and 10 mg) based on tolerance safety. Subjects will remain on 10mg until they complete the study. Dose adjustments may be made based on side effects.</description>
    <arm_group_label>Ambrisentan (24 Weeks), Extension (4 Weeks)</arm_group_label>
    <other_name>Letairis</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Subjects need to fulfill all of the following 4 criteria:&#xD;
&#xD;
          1. Evidence of portal hypertension (by hemodynamic measurement, or by Doppler flow of&#xD;
             portal circulation, or by clinical evidence of portal hypertension such as esophageal&#xD;
             or gastric varices, as evidenced by prior upper endoscopy).&#xD;
&#xD;
          2. Evidence of pulmonary arterial hypertension by right heart catheterization (all three&#xD;
             criteria need to be present) Right heart catheterization may have been performed up to&#xD;
             30 days prior to screening&#xD;
&#xD;
               -  Mean PAP (pulmonary artery pressure) &gt;25 mm Hg, and&#xD;
&#xD;
               -  PVR (pulmonary vascular resistance) &gt;240 dynes/s/cm5, and&#xD;
&#xD;
               -  TPG (transpulmonary gradient = meanPAP -PAWP) &gt;12 mm Hg&#xD;
&#xD;
          3. Baseline AST, ALT &lt; 5 times the upper limit of normal, total Bili &lt; 3.0 mg/dl, and&#xD;
             mild liver impairment with Child -Pugh class A or B&#xD;
&#xD;
          4. Ages 18 years and above&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Presence of any other etiology of pulmonary arterial hypertension (HIV, connective&#xD;
             tissue disease, sickle cell, left heart failure, chronic thromboembolic PH, etc)&#xD;
&#xD;
          2. Treatment with prostacyclins, other ERAs, or PDE5 inhibitors within 30 days of&#xD;
             enrollment.&#xD;
&#xD;
          3. Moribund state or anticipated death within 1 month.&#xD;
&#xD;
          4. AST or ALT ≥ 5 times upper limit of normal&#xD;
&#xD;
          5. Total bilirubin ≥ 3.0 mg/dl&#xD;
&#xD;
          6. Significant lung disease (obstructive lung disease with FEV1 &lt; 1L, or FEV1/FVC &lt;50%;&#xD;
             or restrictive lung disease with Total Lung Capacity &lt; 60% predicted). PFTs may have&#xD;
             been performed up to 6 months prior to enrollment.&#xD;
&#xD;
          7. Pregnancy&#xD;
&#xD;
          8. Age &lt;18 years&#xD;
&#xD;
          9. Child -Pugh class C&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ioana Preston, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tufts Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCSD Medical Center</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Florida</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tufts Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of North Carolina</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Ohio State University Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43221</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UT Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>October 18, 2010</study_first_submitted>
  <study_first_submitted_qc>October 18, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 19, 2010</study_first_posted>
  <results_first_submitted>September 1, 2020</results_first_submitted>
  <results_first_submitted_qc>December 16, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">January 12, 2021</results_first_posted>
  <last_update_submitted>December 16, 2020</last_update_submitted>
  <last_update_submitted_qc>December 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>portopulmonary hypertension</keyword>
  <keyword>portal hypertension</keyword>
  <keyword>esophageal or gastric varices</keyword>
  <keyword>right heart catheterization</keyword>
  <keyword>transpulmonary gradient</keyword>
  <keyword>Endothelin Receptor Antagonist</keyword>
  <keyword>Ambrisentan</keyword>
  <keyword>Letairis</keyword>
  <keyword>pulmonary hemodynamics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension, Pulmonary</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ambrisentan</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Ambrisentan (24 Weeks), Extension (4 Weeks)</title>
          <description>Treatment-naive Group 1 Pulmonary Arterial Hypertension patients with Porto-pulmonary Hypertension with Child-Pugh class A/B were administered with ambrisentan for 24 weeks, followed by a long-term extension (24-28 weeks).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Group 1 Pulmonary Arterial Hypertension with Porto-pulmonary Hypertension</population>
      <group_list>
        <group group_id="B1">
          <title>Ambrisentan (24 Weeks), Extension (4 Weeks)</title>
          <description>Long-term extension of 24-28 weeks of ambrisentan.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50" spread="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>pulmonary vascular resistance</title>
          <units>HRU/Wood units</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.1" spread="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Pulmonary Vascular Resistance</title>
        <description>Change in Pulmonary Vascular Resistance from baseline to Week 24 for all patients (using cardiac output [CO] measured by the thermodilution method and reported as percent difference from baseline).</description>
        <time_frame>from baseline to Week 24</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ambrisentan</title>
            <description>Open Label Ambrisentan&#xD;
Ambrisentan: Ambrisentan once-daily in the morning with or without food. The adult dose selected for this study will be 5 mg for the first 4 weeks. After the initial 4 weeks the dose will be increased to 10mg (available doses are 5, and 10 mg) based on tolerance safety. Subjects will remain on 10mg until they complete the study. Dose adjustments may be made based on side effects.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Pulmonary Vascular Resistance</title>
          <description>Change in Pulmonary Vascular Resistance from baseline to Week 24 for all patients (using cardiac output [CO] measured by the thermodilution method and reported as percent difference from baseline).</description>
          <units>percent difference from baseline</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.1" spread="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>6 Minute Walk Distance</title>
        <description>Change from baseline in 6 Minute Walk Distance to Week 24 for all patients. (difference measured in meters).</description>
        <time_frame>Change from baseline to Week 24</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1 PAH With PoPH</title>
            <description>Treatment-naive Group 1 PAH patients with PoPH with Child-Pugh class A/B were administered with ambrisentan for 24 weeks, followed by a long-term extension (24-28 weeks).</description>
          </group>
        </group_list>
        <measure>
          <title>6 Minute Walk Distance</title>
          <description>Change from baseline in 6 Minute Walk Distance to Week 24 for all patients. (difference measured in meters).</description>
          <units>meters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="314" spread="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="336" spread="108"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Ambrisentan (24 Weeks), Extension (4 Weeks)</title>
          <description>Treatment-naive Group 1 Pulmonary Arterial Hypertension patients with Porto-pulmonary Hypertension with Child-Pugh class A/B were administered with ambrisentan for 24 weeks, followed by a long-term extension (24-28 weeks).</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Edema</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Leg Edema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Standardization of the 6 Minute Walk Test</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Ioana Preston MD</name_or_title>
      <organization>Tufts Medical Center</organization>
      <phone>617-636-7609</phone>
      <email>ipreston@tuftsmedicalcenter.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

